A pivotal Phase III study of lurbinectedin

Trial Profile

A pivotal Phase III study of lurbinectedin

Planning
Phase of Trial: Phase III

Latest Information Update: 26 May 2017

At a glance

  • Drugs Lurbinectedin (Primary)
  • Indications Breast cancer; Haematological malignancies; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Sarcoma; Small cell lung cancer; Solid tumours
  • Focus Registrational; Therapeutic Use
  • Sponsors PharmaMar
  • Most Recent Events

    • 26 May 2017 New trial record
    • 19 May 2017 According to a PharmaMar media release, the company has reached an agreement with the US FDA on the design of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top